In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Executive Summary

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.

Related Content

Archemix Reduces Aperture to Pursue Orphan Diseases
Isis: Pondering Platform Power
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Can't Say No: Pharma's Addiction to Shareholder Payouts
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Pharma's New Follow-On Strategy
EPO Market Stabilizes, But For How Long?
Genzyme: Why Diversification is Starting to Look Smart
Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
Europe's Flavors of Sustainable BioPharma


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts